181 related articles for article (PubMed ID: 37737967)
21. Quantitative analysis of γ-H2AX and p53 nuclear expression levels in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies in BRCA1 and BRCA2 mutation carriers.
Staff S; Tolonen T; Laasanen SL; Mecklin JP; Isola J; Mäenpää J
Int J Gynecol Pathol; 2014 May; 33(3):309-16. PubMed ID: 24681744
[TBL] [Abstract][Full Text] [Related]
22. MYC is sufficient to generate mid-life high-grade serous ovarian and uterine serous carcinomas in a p53-R270H mouse model.
Blackman A; Rees AC; Bowers RR; Jones CM; Vaena SG; Clark MA; Carter S; Villamor ED; Evans D; Emanuel AJ; Fullbright G; Long DT; Spruill L; Romeo MJ; Helke KL; Delaney JR
bioRxiv; 2024 Jan; ():. PubMed ID: 38352443
[TBL] [Abstract][Full Text] [Related]
23. Somatic Mutational Profile of High-Grade Serous Ovarian Carcinoma and Triple-Negative Breast Carcinoma in Young and Elderly Patients: Similarities and Divergences.
Serio PAMP; de Lima Pereira GF; Katayama MLH; Roela RA; Maistro S; Folgueira MAAK
Cells; 2021 Dec; 10(12):. PubMed ID: 34944094
[TBL] [Abstract][Full Text] [Related]
24. MiR-585-3p suppresses tumor proliferation and migration by directly targeting CAPN9 in high grade serous ovarian cancer.
Lu X; Li G; Liu S; Wang H; Chen B
J Ovarian Res; 2021 Jul; 14(1):90. PubMed ID: 34238324
[TBL] [Abstract][Full Text] [Related]
25. Better or worse? The prognostic role of the mesenchymal subtype in patients with high-grade serous ovarian carcinoma: A systematic review and meta-analysis.
Chen J; Shi X; Xiao L; Li Z; Li Z; Sun L
Cancer Med; 2022 Oct; 11(20):3761-3770. PubMed ID: 35434908
[TBL] [Abstract][Full Text] [Related]
26. BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma.
McAlpine JN; Porter H; Köbel M; Nelson BH; Prentice LM; Kalloger SE; Senz J; Milne K; Ding J; Shah SP; Huntsman DG; Gilks CB
Mod Pathol; 2012 May; 25(5):740-50. PubMed ID: 22282309
[TBL] [Abstract][Full Text] [Related]
27. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
[TBL] [Abstract][Full Text] [Related]
28. Identification of candidate genes associated with tubal origin of high-grade serous ovarian cancer.
Xiang L; Rong G; Zhao J; Wang Z; Shi F
Oncol Lett; 2018 May; 15(5):7769-7775. PubMed ID: 29731902
[TBL] [Abstract][Full Text] [Related]
29. CCNG1 (Cyclin G1) regulation by mutant-P53 via induction of Notch3 expression promotes high-grade serous ovarian cancer (HGSOC) tumorigenesis and progression.
Xu Y; Zhang Q; Miao C; Dongol S; Li Y; Jin C; Dong R; Li Y; Yang X; Kong B
Cancer Med; 2019 Jan; 8(1):351-362. PubMed ID: 30565428
[TBL] [Abstract][Full Text] [Related]
30. The Prognostic Significance of Tumor-Infiltrating Lymphocytes, PD-L1, BRCA Mutation Status and Tumor Mutational Burden in Early-Stage High-Grade Serous Ovarian Carcinoma-A Study by the Spanish Group for Ovarian Cancer Research (GEICO).
Pizarro D; Romero I; Pérez-Mies B; Redondo A; Caniego-Casas T; Carretero-Barrio I; Cristóbal E; Gutiérrez-Pecharromán A; Santaballa A; D'Angelo E; Hardisson D; Vieites B; Matías-Guiu X; Estévez P; Guerra E; Prat J; Poveda A; López-Guerrero JA; Palacios J
Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446361
[TBL] [Abstract][Full Text] [Related]
31. ROR2 induces cell apoptosis via activating IRE1α/JNK/CHOP pathway in high-grade serous ovarian carcinoma in vitro and in vivo.
Li R; Liu T; Shi J; Luan W; Wei X; Yu J; Mao H; Liu P
J Transl Med; 2019 Dec; 17(1):428. PubMed ID: 31878941
[TBL] [Abstract][Full Text] [Related]
32. Exploring the Role of Fallopian Ciliated Cells in the Pathogenesis of High-Grade Serous Ovarian Cancer.
Coan M; Rampioni Vinciguerra GL; Cesaratto L; Gardenal E; Bianchet R; Dassi E; Vecchione A; Baldassarre G; Spizzo R; Nicoloso MS
Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30149579
[TBL] [Abstract][Full Text] [Related]
33. Molecular characterization of high-grade serous ovarian cancers occurring in younger and older women.
Filippova OT; Selenica P; Pareja F; Vahdatinia M; Zhu Y; Pei X; Riaz N; Long Roche K; Chi DS; Abu-Rustum NR; Ellenson LH; Reis-Filho JS; Zamarin D; Weigelt B
Gynecol Oncol; 2021 May; 161(2):545-552. PubMed ID: 33674143
[TBL] [Abstract][Full Text] [Related]
34. miR-145 inhibits tumor growth and metastasis by targeting metadherin in high-grade serous ovarian carcinoma.
Dong R; Liu X; Zhang Q; Jiang Z; Li Y; Wei Y; Li Y; Yang Q; Liu J; Wei JJ; Shao C; Liu Z; Kong B
Oncotarget; 2014 Nov; 5(21):10816-29. PubMed ID: 25333261
[TBL] [Abstract][Full Text] [Related]
35. Modeling high-grade serous ovarian carcinogenesis from the fallopian tube.
Karst AM; Levanon K; Drapkin R
Proc Natl Acad Sci U S A; 2011 May; 108(18):7547-52. PubMed ID: 21502498
[TBL] [Abstract][Full Text] [Related]
36. Hereditary Ovarian Carcinoma: Cancer Pathogenesis Looking beyond
Samuel D; Diaz-Barbe A; Pinto A; Schlumbrecht M; George S
Cells; 2022 Feb; 11(3):. PubMed ID: 35159349
[TBL] [Abstract][Full Text] [Related]
37. Natural history of ovarian high-grade serous carcinoma from time effects of ovulation inhibition and progesterone clearance of p53-defective lesions.
Wu NY; Fang C; Huang HS; Wang J; Chu TY
Mod Pathol; 2020 Jan; 33(1):29-37. PubMed ID: 31558785
[TBL] [Abstract][Full Text] [Related]
38. SOCS7/HuR/FOXM1 signaling axis inhibited high-grade serous ovarian carcinoma progression.
Du Y; Xu X; Lv S; Liu H; Sun H; Wu J
J Exp Clin Cancer Res; 2022 May; 41(1):185. PubMed ID: 35624501
[TBL] [Abstract][Full Text] [Related]
39. NF-κB-miR-155 axis activation mediates ovulation-induced oncogenic effects in fallopian tube epithelium.
Brand H; Barnabas GD; Sapoznik S; Bahar-Shany K; Pozniak Y; Yung Y; Hourvitz A; Geiger T; Jacob-Hirsch J; Levanon K
Carcinogenesis; 2020 Dec; 41(12):1703-1712. PubMed ID: 32614381
[TBL] [Abstract][Full Text] [Related]
40. miR-106a represses the Rb tumor suppressor p130 to regulate cellular proliferation and differentiation in high-grade serous ovarian carcinoma.
Liu Z; Gersbach E; Zhang X; Xu X; Dong R; Lee P; Liu J; Kong B; Shao C; Wei JJ
Mol Cancer Res; 2013 Nov; 11(11):1314-25. PubMed ID: 24045973
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
